COVID-19, más allá de la enfermedad

Yuri Valeria  Alzate Cuevas; Andrea del Pilar  Álvarez-Sánchez1; Laura Alejandra Bejarano Avendano; Iván Alberto  Méndez Rodríguez3

doi:10.26752/cuarzo.v30.n1.664

COVID-19, beyond the disease?

COVID-19, más allá de la enfermedad

Article Sidebar

Pdf (Español (España))

FLIP

How to Cite

Alzate Cuevas, Y. V. ., Álvarez-Sánchez1, A. del P. ., Bejarano Avendano, L. A., & Méndez Rodríguez3, I. A. . (2024). COVID-19, beyond the disease?. Revista Cuarzo, 30(1), 14–25. https://doi.org/10.26752/cuarzo.v30.n1.664

ACM
APA
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver

Published: Jun 30, 2024

Doi

https://doi.org/10.26752/cuarzo.v30.n1.664

Dimensions

PlumX

Issue

Vol. 30 No. 1 (2024)

Section

Artículos de revisión

License terms

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Main Article Content

Yuri Valeria Alzate Cuevas

Nueva Granada Military University

Andrea del Pilar Álvarez-Sánchez1

Nueva Granada Military University

Roles:

Writing - review and editing

Laura Alejandra Bejarano Avendano

Nueva Granada Military University

Iván Alberto Méndez Rodríguez3

Nueva Granada Military University

Abstract

Background: Since the first case reported of COVID-19, disease caused by the SARS-CoV-2, has been characterized by a variable clinic presentation whose main manifestations are the respiratory ones, it created an impact not just in public health, but also in the different fields of modern science, representing a challenge for research. For this reason, the present review tries to synthesize the relevant information about the etiology, physiopathology, clinic presentation, diagnostic and treatment of this novel disease; taking into account the dynamic process of information which is updated in some aspects periodically.

Keywords:

Covid-19

Global Health

Coronavirus

COVID-19

Coronavirus

Salud Global

Downloads

Download data is not yet available.

Article Details

Author Biographies (SEE)

Yuri Valeria Alzate Cuevas, Nueva Granada Military University

Medical School, New Granada Military University, Bogotá, Colombia

Andrea del Pilar Álvarez-Sánchez1, Nueva Granada Military University

Medical School, New Granada Military University, Bogotá, Colombia

Laura Alejandra Bejarano Avendano, Nueva Granada Military University

Students of the Faculty of Medicine, 8th semester. New Granada Military University, Bogotá, Colombia

Iván Alberto Méndez Rodríguez3, Nueva Granada Military University

Master's in Microbiology, Infectious Diseases Professor, Faculty of Medicine, Faculty of Sciences, New Granada Military University, Bogotá, Colombi

References (SEE)

Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–24. DOI: 10.4014/jmb.2003.03011 DOI: https://doi.org/10.4014/jmb.2003.03011

Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. Rev Clínica Española. 2021;221(1):55–61. DOI: 10.1016/j.rce.2020.03.001 DOI: https://doi.org/10.1016/j.rce.2020.03.001

Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019 -COVID-19. Clin Microbiol Rev [Internet]. 2020;33(4):1–48. Available from: DOI: https://doi.org/10.1128/CMR.00028-20 DOI: https://doi.org/10.1128/CMR.00028-20

Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667–73. DOI: 10.1016/j.jiph.2020.03.019 DOI: https://doi.org/10.1016/j.jiph.2020.03.019

Centros para el Control y la prevención de Enfermedades. Sindrome respiratorio agudo severo. C.D.F. 2004. https://www.cdc.gov/sars/index-sp.html

Yang Y, Xiao Z, Ye K, He X, Sun B, Qin Z, et al. SARS-CoV-2: characteristics and current advances in research. Virol J. 2020;17(1):1–17. DOI: https://doi.org/10.1186/s12985-020-01369-z DOI: https://doi.org/10.1186/s12985-020-01369-z

Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–44. DOI: 10.1016/S1473-3099(20)30484-9. DOI: https://doi.org/10.1016/S1473-3099(20)30484-9

Díaz-Castrillón FJ, Toro-Montoya AI. SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia. Med y Lab. 2020;24(3):183–205. DOI: https://doi.org/10.36384/01232576.268 DOI: https://doi.org/10.36384/01232576.268

José FG, González JGÁ, Molina JMC, Arnau LB, Iribarren IM, Jabaloyas JMM, et al. SARS-CoV-2 infection: implications for sexual and reproductive health. A position statement of the Asociación Española de Andrología, Medicina Sexual y Reproductiva (ASESA). Rev Int Androl. 2020;18(3):117–23. DOI: 10.1016/j.androl.2020.06.001. DOI: https://doi.org/10.1016/j.androl.2020.06.001

Yuki K et al. Review Article COVID-19 pathophysiology: A review. Clin Immunol [Internet]. 2020;215(January):1–8. DOI https://doi.org/10.1016/j.clim.2020.108427 DOI: https://doi.org/10.1016/j.clim.2020.108427

Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36. DOI: 10.1080/22221751.2020.1719902 DOI: https://doi.org/10.1080/22221751.2020.1719902

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2021. Available from: https://covid19.who.int

Social M de S y P. Colombia confirma su primer caso de COVID-19 [Internet]. Boletin de prensa No. 050 de 2020. 2020. Available from: https://www.minsalud.gov.co/Paginas/Colombia-confirma-su-primer-caso-de-COVID-19.aspx

Toledo JD, Bernal C, Ramírez B, Rodríguez S, Vallejo M, Rivera D, et al. SEGUIMIENTO COVID-19 COLOMBIA 30 -SEPTIEMBRE-2020 Dia 206 del Brote en Colombia. Bogotá D.C; 2020.Fuente: Comunicación personal.

Organización Panamericana de la Salud. Indicadores incidencia y Gravedad Actualización situación COVID-19 Colombia. Inst Nac Salud, Obs Nac Salud. 2020;(151):1–9. https://www.paho.org/es/reportes-situacion-covid-19-colombia

Organización Panamericana de la Salud. Reporte de Situacion COVID-19 Colombia No. 206 - 02 de febrero 2021 Indicadores de incidencia. Colombia; 2020. https://www.paho.org/es/reportes-situacion-covid-19-colombia

Care E point of. Coronavirus: novel coronavirus (COVID-19) infection. Elsevier. 2020. p. 1–46. https://www.elsevier.com/__data/assets/pdf_file/0011/990722/Coronavirus-novel-coronavirus-COVID-19-infection-CO-200520.pdf

Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–9. DOI: 10.1164/rccm.202003-0543OC DOI: https://doi.org/10.1164/rccm.202003-0543OC

Thapa K, Mph B, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2020;49(January):238–46. DOI: 10.1016/j.ajic.2020.06.213 DOI: https://doi.org/10.1016/j.ajic.2020.06.213

Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis, and treatment of COVID-19. J Antimicrob agents. 2020;55(January):1–13. DOI: 10.1016/j.ijantimicag.2020.105955 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105955

Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019- nCoV) infections among travellers from Wuhan, China, 20 28 January 2020. Eurosurveillance. 2020;25(5):1–6. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062 DOI: https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000062

Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100–15. DOI: 10.1016/j.it.2020.10.004 DOI: https://doi.org/10.1016/j.it.2020.10.004

Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(January):607–13. DOI 10.1016/j.jinf.2020.03.037 DOI: https://doi.org/10.1016/j.jinf.2020.03.037

Alves A, Quispe A, Ávila A, Valdivia A, Chino J, Vera O. Breve historia y fisiopatologia del COVID-19. Guia Diagnostico y Trat COVID-19 en Unidades Ter Intensiva para Boliv. 2020;61(1):77–86. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-807138

Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertens y riesgo Vasc. 2020;37(4):176–80. DOI: 10.1016/j.hipert.2020.06.003 DOI: https://doi.org/10.1016/j.hipert.2020.06.003

Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020;43(10):1028–46. DOI: 10.1038/s41440-020-0515-0 DOI: https://doi.org/10.1038/s41440-020-0515-0

Kanwal A, Agarwala A, Warsinger Martin L, Handberg EM, Yang E. COVID-19 and Hypertension: What We Know and Don’t Know [Internet]. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/15/covid-19-and-hypertension

Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis. Polish Arch Intern Med. 2020;130(4):304–9. DOI: 10.20452/pamw.15272 DOI: https://doi.org/10.20452/pamw.15272

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. DOI: 10.1016/j.jemermed.2020.04.004 DOI: https://doi.org/10.1056/NEJMoa2002032

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. DOI: 10.1111/joim.13091 DOI: https://doi.org/10.1111/joim.13091

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34(March):101623. DOI: 10.1016/j.tmaid.2020.101623 DOI: https://doi.org/10.1016/j.tmaid.2020.101623

Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5. DOI: 10.1002/jmv.25728 DOI: https://doi.org/10.1002/jmv.25728

Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol - Head Neck Surg (United States). 2020;163(1):3–11. DOI: 10.1177/0194599820926473 DOI: https://doi.org/10.1177/0194599820926473

Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatology Venereol. 2020;34(5):e212–3. DOI: 10.1111/jdv.16387 DOI: https://doi.org/10.1111/jdv.16387

Yan Z, Wei C, Meng X, Yuanjie L, Yang Y, Jing Z, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. Chinese J Hematol [Internet]. 2020;41(04):302–7. Available from: DOI: 10.3760/cma.j.issn.0253-2727.2020.008

Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700. DOI: 10.1016/j.jaad.2020.04.018 DOI: https://doi.org/10.1016/j.jaad.2020.04.018

OMS. Síndrome inflamatorio multisistémico en niños y adolescentes con COVID-19. Inf científico. 2020;1–3. WHO reference number: WHO/2019-nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1

Organización Panamericana de la Salud / Organización Mundial de la Salud. Alerta Epidemiológica complicaciones y secuelas por. Ops/Oms. 2020; https://www.paho.org/es/documentos/alerta-epidemiologica-complicaciones-secuelas-por-covid-19-12-agosto-2020

Grupo ACIN. Consenso Colombiano de atención, diagnóstico y manejo de la infección por SARS-CoV-2/COVID-19 en establecimientos de atención de la salud. INFECTIO [Internet]. 2020;24(3):14–24. Available from: http://www.iets.org.co/Archivos/853-2765-1-PB.pdf DOI: https://doi.org/10.22354/in.v24i3.851

Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87–93. doi: 10.2214/AJR.20.23034 DOI: https://doi.org/10.2214/AJR.20.23034

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5 DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Med J Chinese People’s Lib Army. 2020;45(1):1–20. DOI: 10.1186/s40779-020-0233-6 DOI: https://doi.org/10.1186/s40779-020-0233-6

Cheng VC, Edwards KM, Gandhi R, Muller WJ. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. 2020. DOI: 10.1093/cid/ciaa478 DOI: https://doi.org/10.1093/cid/ciaa478

Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–32. DOI: 10.1080/22221751.2020.1746199 DOI: https://doi.org/10.1080/22221751.2020.1746199

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020;1–13. DOI : 10.1056/NEJMoa2031994

Food and drug administration. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 [Internet]. 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–31. DOI: 10.1056/NEJMoa2022483 DOI: https://doi.org/10.1056/NEJMoa2022483

Pfizer. PFIZER AND BIONTECH ACHIEVE FIRST AUTHORIZATION IN THE WORLD FOR A VACCINE TO COMBAT COVID-19 [Internet]. 2020. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world

Pfizer. PFIZER AND BIONTECH ANNOUNCE PUBLICATION OF RESULTS FROM LANDMARK PHASE 3 TRIAL OF BNT162B2 COVID-19 VACCINE CANDIDATE IN THE NEW ENGLAND JOURNAL OF MEDICINE [Internet]. 2020. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark

Randall T, Sam C, Tartar A, Murray P, Cannon C. COVID 19 vaccine tracker global distribution [Internet]. 2021. Available from: https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/

WHO. Status of COVID-19 Vaccines within WHO EUL / PQ evaluation process. Who. 2021;26(December 2020):2020–2.

(FDA) TU. F and DA. EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19). 2021. p. 1–30. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use

Centros para el Control y la prevención de Enfermedades. Pfizer-BioNTech [Internet]. 2021 [cited 2021 Feb 6]. Available from: https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. DOI: 10.1016/S1473-3099(20)30843-4 DOI: https://doi.org/10.1016/S1473-3099(20)30843-4

Bischler A. Dosing information for AstraZeneca COVID-19 Vaccine [Internet]. 13 January. 2021 [cited 2021 Feb 5]. Available from: https://www.sps.nhs.uk/articles/dosing-information-for-astrazeneca-covid-19-vaccine/

AstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. 3 February. 2021 [cited 2021 Feb 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html

Products M& H, Regulatory Agency. Information for Healthcare Professionals on COVID- 19 Vaccine AstraZeneca. 2021. p. 1–14. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca-regulation-174

Instituto de Efectividad Clínica y Sanitaria (IECS). Vacunas contra COVID-19 2. 2020. p. 1–18. Avaible at: https://docs.bvsalud.org/biblioref/2020/12/1140939/iecs-irr-814-va-1-3.pdf

National Institutes of Health. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released [Internet]. January 29. 2021. Available from: https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released

Levine H. COVID-19 Update: Your Latest Questions About Johnson & Johnson’s Investigational Vaccine Candidate Answered [Internet]. 2021 [cited 2021 Feb 5]. Available from: https://www.jnj.com/innovation/questions-about-johnson-johnson-investigational-covid-19-vaccine

Batres O. Vacuna Covid Janssen: la dosis única genera anticuerpos en el 90% de casos [Internet]. Redacción médica. 2021 [cited 2021 Feb 5]. Available from: https://www.redaccionmedica.com/secciones/sanidad-hoy/vacuna-covid-janssen-dosis-unica-anticuerpos-5331

Branswell H. Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson [Internet]. STAT. 2021 [cited 2021 Feb 5]. Available from: https://www.statnews.com/2021/02/02/comparing-the-covid-19-vaccines-developed-by-pfizer-moderna-and-johnson-johnson/

Microbiology TGNC of E and. Sputnik V, The first registered COVID-19 vaccine proven human adenoviral vector technology [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://sputnikvaccine.com/esp/about-vaccine/

Ministerio de Salud de Argentina. Campaña Nacional de Vacunación contra la COVID-19. 2o informe de vigilancia de seguridad de vacunas. [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://www.fundacionfemeba.org.ar/blog/farmacologia-7/post/efectos-adversos-de-la-vacuna-sputnik-v-48739

##citations_tittle##